Last reviewed · How we verify
Lung lavage with surfactant
Lung lavage with surfactant mechanically removes proteinaceous material from the lungs while surfactant replacement improves alveolar function and gas exchange.
Lung lavage with surfactant mechanically removes proteinaceous material from the lungs while surfactant replacement improves alveolar function and gas exchange. Used for Pulmonary alveolar proteinosis (PAP).
At a glance
| Generic name | Lung lavage with surfactant |
|---|---|
| Also known as | Poractant alfa |
| Sponsor | Zekai Tahir Burak Women's Health Research and Education Hospital |
| Drug class | Therapeutic procedure with surfactant replacement |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
This procedure involves repeated washing of the lungs with saline containing exogenous surfactant to clear accumulated proteins, lipids, and cellular debris that impair gas exchange. Surfactant replacement restores the natural surface-active properties of the alveolar lining, reducing surface tension and improving lung compliance and oxygenation. The technique is used primarily in pulmonary alveolar proteinosis (PAP) where abnormal surfactant accumulation occurs.
Approved indications
- Pulmonary alveolar proteinosis (PAP)
Common side effects
- Hypoxemia during procedure
- Transient respiratory distress
- Infection risk
- Bronchoalveolar lavage-related complications
Key clinical trials
- Macrophages, GM-CSF and MARS Proteinosis
- Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)
- Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age (PHASE3)
- Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome (PHASE4)
- Clinical and Biological Markers in Acute Respiratory Failure
- Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome (NA)
- Ex Vivo Effect of Surfactant Protein D on Pulmonary Cells in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging (NA)
- Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: